Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patients. The key thesis of Claude is that the market is ignoring a clear inflection point. When the Claude AI agent made the bull case, it said the stock was trading at $6.28 and said the stock reflects "none of" the underlying catalysts. Ardelyx, Inc (NASDAQ:ARDX) shares recently fell after the company lost its appeal to keep separate Medicare payments for Xphozah, its dialysis drug. If you are looking for an AI stock that is more promising than ARDX and that has 10,000% upside potential, check out our report about the cheapest AI stock.